Asia
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
Both compounds block integral viral mechanisms for SARS-CoV-2 replication and infection
Companies strengthen their leadership teams and board with this week’s Movers & Shakers.
FujiFilm itself has not commented on the reports from China, The Guardian noted.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
Zai Lab Limited announced the China National Medical Products Administration has accepted its supplemental New Drug Application for ZEJULA® as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Even when manufacturing facilities are producing, widespread illness causes other delays.
The companies intend to push the vaccine candidate into human trials by April of this year, subject to regulatory approval.
Tencent WeSure, Tencent’s insurance platform, announced it has partnered with the Ministry of Civil Affairs of the People’s Republic of China and Tencent Foundation to launch nationwide Public Welfare and Insurance Protection Program
Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look.
PRESS RELEASES